All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

How do we treat high-risk patients outside of a clinical trial?

The MDS Hub Steering Commitee met on May 5, 2022. The recorded discussion was chaired by Theo de Witte, and featured Rena Buckstein, and Yasushi Miyazaki. The topic of this discussion, “How do we treat high-risk patients outside of a clinical trial?”, was identified as an unmet educational need within MDS treatment.

 

How do we treat high-risk patients outside of a clinical trial?

De Witte discusses approaches to treat high-risk patients, including following the current guidelines in MDS treatment, and potential new drugs that may become approved by the U.S. Food and Drug Administration (FDA). Buckstein discusses the use of hypomethylating agents, and what factors she considers when treating patients with these drugs, such as cytotoxicity. Miyazaki talks about using azacitadine in high-risk patients, following the Japanese guidelines.